Predictive Oncology (POAI) Competitors

CollPlant Biotechnologies (NASDAQ:CLGN) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Do analysts prefer CLGN or POAI?

CollPlant Biotechnologies presently has a consensus target price of $11.50, indicating a potential upside of 405.49%. Predictive Oncology has a consensus target price of $3.00, indicating a potential upside of 279.27%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, research analysts clearly believe CollPlant Biotechnologies is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Predictive Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more volatility & risk, CLGN or POAI?

CollPlant Biotechnologies has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Does the media favor CLGN or POAI?

In the previous week, Predictive Oncology had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for Predictive Oncology and 1 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 1.89 beat Predictive Oncology's score of 1.23 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
CollPlant Biotechnologies	Very Positive
Predictive Oncology	Positive

Which has stronger valuation & earnings, CLGN or POAI?

Predictive Oncology has lower revenue, but higher earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.47M	11.70	-$16.61M	-$1.22	-1.86
Predictive Oncology	$1.73M	4.68	-$12.66M	-$3.05	-0.26

Is CLGN or POAI more profitable?

CollPlant Biotechnologies has a net margin of -560.92% compared to Predictive Oncology's net margin of -629.68%. CollPlant Biotechnologies' return on equity of -87.33% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-560.92%	-87.33%	-65.31%
Predictive Oncology	-629.68%	-671.29%	-132.49%

Do institutionals and insiders have more ownership in CLGN or POAI?

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 3.4% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CollPlant Biotechnologies beats Predictive Oncology on 14 of the 17 factors compared between the two stocks.